Avantor (NYSE:AVTR) Price Target Cut to $26.00 by Analysts at Raymond James

Avantor (NYSE:AVTR) had its price objective reduced by Raymond James from $29.00 to $26.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

AVTR has been the subject of a number of other reports. UBS Group reiterated a “neutral” rating and issued a $25.00 price target (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Barclays cut their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada restated an “outperform” rating and set a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th. Robert W. Baird cut their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Finally, Wells Fargo & Company cut their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.38.

Avantor Stock Performance

Shares of AVTR stock opened at $21.89 on Tuesday. The company has a 50 day moving average price of $21.46 and a 200-day moving average price of $23.39. Avantor has a 52 week low of $19.59 and a 52 week high of $28.00. The firm has a market capitalization of $14.90 billion, a PE ratio of 47.59, a P/E/G ratio of 3.48 and a beta of 1.28. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Hedge Funds Weigh In On Avantor

Several hedge funds have recently modified their holdings of the stock. Hantz Financial Services Inc. raised its stake in Avantor by 2.1% during the third quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock valued at $644,000 after purchasing an additional 503 shares in the last quarter. Intech Investment Management LLC grew its holdings in Avantor by 1.8% during the 2nd quarter. Intech Investment Management LLC now owns 29,068 shares of the company’s stock worth $616,000 after acquiring an additional 514 shares in the last quarter. Blue Trust Inc. increased its position in Avantor by 6.9% during the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock valued at $170,000 after purchasing an additional 522 shares during the period. Pacer Advisors Inc. increased its position in Avantor by 0.5% during the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock valued at $2,103,000 after purchasing an additional 542 shares during the period. Finally, Veracity Capital LLC increased its position in Avantor by 1.0% during the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock valued at $1,355,000 after purchasing an additional 543 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.